Wen, Yu-Ching
Chen, Wei-Yu
Tram, Van Thi Ngoc
Yeh, Hsiu-Lien
Chen, Wei-Hao
Jiang, Kuo-Ching
Abou-Kheir, Wassim
Huang, Jiaoti http://orcid.org/0000-0003-1195-1998
Hsiao, Michael http://orcid.org/0000-0001-8529-9213
Liu, Yen-Nien http://orcid.org/0000-0002-3102-8482
Funding for this research was provided by:
Taipei Medical University (110TMU-WFH-06)
Ministry of Science and Technology, Taiwan (MOST 109-2326-B-038 -001-MY3, MOST110-2622-B-038-002)
National Health Research Institutes (NHRI-EX111-11109BI)
Article History
Received: 29 October 2021
Revised: 17 February 2022
Accepted: 25 February 2022
First Online: 19 March 2022
Competing interests
: The authors declare no competing interests.
: The use of PCa TMA sections from Duke University School of Medicine (Durham, NC, USA) was approved by the Duke University School of Medicine Institutional Review Board (protocol ID: Pro00070193). Tumor samples of PCa patients before and after ADT treatment were collected from Taipei Medical University-associated Wan Fang Hospital following the <i>Declaration of Helsinki</i>, and the study protocol was approved by the Taipei Medical University Joint Institutional Review Board (approval ID: N202001020).